Xcout IntelLakefront Biotherapeutics NV
Galapagos NV is a biotechnology company that specializes in the discovery and advancement of novel small molecule and antibody-based therapeutics. Its active clinical development programs include drugs like filgotinib and GLP3667, alongside the Toledo program and therapies targeting idiopathic pulmonary fibrosis. The firm was established on June 30, 1999, by co-founders Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es, and maintains its headquarters in Mechelen, Belgium.
Subscribe to see Lakefront Biotherapeutics NV’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Lakefront Biotherapeutics NV at a glance
Lakefront Biotherapeutics NV is a biotech company headquartered in Mechelen, Belgium. It is publicly listed (LKFT) with a market capitalisation of $1.8B. Xcout tracks 18 named people at Lakefront Biotherapeutics NV, including Henry Gosebruch (CEO & Executive Director).
Lakefront Biotherapeutics NV leadership
- Henry GosebruchCEO & Executive Director
- Christina CarlsonChief Operating Officer
- Aaron CoxChief Financial Officer
- Aaron L. CoxChief Financial Officer
- Dan GrossmanChief Strategy Officer
- Eric HedrickChief Medical Officer
12 more named people on record for Lakefront Biotherapeutics NV, with roles, board committees and tenure — see the full roster →
Lakefront Biotherapeutics NV competitors
A few of Lakefront Biotherapeutics NV's closest competitors — see the full list of competitors and alternatives →
AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.
Galecto Biotech is a biotechnology company developing small-molecule inhibitors targeting galectin proteins and related pathways, with applications in fibrotic diseases and cancer. Its products are intended for patients and healthcare providers, particularly in areas with limited treatment options.
Argenx NV is a global immunology company that researches, develops, and commercializes antibody-based therapies for patients suffering from severe autoimmune diseases. The company's proprietary product portfolio includes treatments such as VYVGART and VYVGART Hytrulo, which are designed to target and address pathogenic antibodies.
Mestag Therapeutics is an immunotherapy company focusing on fibroblast-immune biology to address critical unmet needs in inflammatory diseases and oncology. The company operates across hubs including Cambridge, United Kingdom, and Ghent, Belgium.
Oxurion N.V. is a biopharmaceutical enterprise dedicated to the research, development, and marketing of innovative treatments for ocular diseases, operating both within Belgium and across international markets. Its primary commercialized therapy is JETREA, prescribed for vitreomacular adhesion and vitreomacular traction. Beyond this, Oxurion's clinical pipeline includes two promising compounds in Phase II trials for diabetic macular edema (DME): THR-149, which functions as a plasma kallikrein inhibitor, and THR-687, an integrin antagonist. The company also fosters collaborative relationships with Bicycle Therapeutics, INC Research, and Galapagos NV. Founded in 1991, this Leuven, Belgium-headquartered firm adopted its current name, Oxurion N.V., in September 2018, having previously operated as ThromboGenics NV.
Get Lakefront Biotherapeutics NV's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Lakefront Biotherapeutics NV in Xcout Intel
- 18 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access